SCHEMBL5149290

SCHEMBL5149290

CC(C)n1nc(-c2nc(N3CCN(c4ccccn4)CC3)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.43
ALDH1A1 P00352 5/20 0.43
HTT P42858 4/20 0.43
MAPT P10636 4/20 0.43
KMT2A Q03164 3/20 0.43
NPSR1 Q6W5P4 3/20 0.43
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 4/20 0.40
HSD17B10 Q99714 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TP53 P04637 2/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 2/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
MAPK1 P28482 3/20 0.39
DHFR P00374 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
POLB P06746 1/20 0.39
HK1 P19367 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149109 0.88 HRH4 (0.43) ALDH1A1HTTMAPTNPSR1SMN1; SMN2
SCHEMBL5151108 0.88 HRH3 (0.39) MAPTKMT2ANPSR1MEN1HSD17B10
SCHEMBL5152699 0.87 MAPT (0.40) LMNAALDH1A1HTTMAPTKMT2A
SCHEMBL5149172 0.87 KDM4E (0.40) LMNAALDH1A1MAPTKMT2ANPSR1
SCHEMBL5149031 0.86 ALDH1A1 (0.41) LMNAALDH1A1HTTMAPTKMT2A
SCHEMBL5150733 0.85 ATR (0.37) ALDH1A1HSD17B10HPGDHIF1A
SCHEMBL5150685 0.85 HSD17B10 (0.42) LMNAALDH1A1HTTMAPTKMT2A
SCHEMBL5152349 0.84 SMO (0.46) ALDH1A1HTTMAPTNPSR1KDM4E
SCHEMBL5149198 0.82 SIRT1 (0.43) LMNAALDH1A1MAPTKMT2ANPSR1
SCHEMBL5147939 0.81 HRH3 (0.39) HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265120-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2007-09-04 US disclosed
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222159-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, HTR5A, ADORA1 LMNA 2809/4885ALDH1A1 748/4885HTT 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.